Finally, we demonstrate proof-of-concept anti-tumor efficacy in a demonstrably 5-FU-resistant CRC xenograft model with a first-in-class direct GLI1 inhibitor, SRI-38832. Here, GLI1 is linked to colorectal carcinoma.